Studies evaluating knowledge and attitudes of oncologists regarding tumor next-generation sequencing
| Study . | Country . | Sample size . | Physicians . | Type of survey . | Dimensions and measures . | Main findings . |
|---|---|---|---|---|---|---|
| Chow-White 2017 | Canada | 31 | Medical oncologists (actively involved in clinical genomics trial) | Web-based questionnaire | Knowledge (self-perceived) Attitudes, concerns, and expectations regarding primary results | Low to moderate level of genomic literacy 42% thought medical training programs do not offer enough genomic training Majority thought genomics will have a major impact on drug discovery and treatment selection in the next 5 years Major challenges considered to be cost, patient genomic literacy, and clinical utility of genomics |
| Gray 2016 | U.S. | 27 | Medical oncologists with extensive experience ordering tumor NGS (median 100 per year) | Self-administered questionnaire (in person or by telephone) Follow-up interview | Knowledge (self-perceived) Attitudes about return of results | 97% moderately to very confident in their ability to interpret somatic results in their disease area, to explain concepts to patients, and to make treatment recommendations based on somatic information 78% wanted to disclose results if they have clinical utility, 67% if no clinical utility Some expressed concern about management of patients’ expectations and how much of the information should be shared with patients |
| Gray 2014 | U.S. | 160 | Medical, radiation, and surgical oncologists | Web survey | Knowledge (self-perceived) Attitudes and expectations regarding primary results Attitude toward secondary findings | Considerable variation in genomic confidence with 22% reporting low confidence in genomic knowledge Higher genomic confidence was associated with wanting to test a majority of patients Variation in attitudes about value of testing Between 70% and 90% endorsed disclosure of actionable or potentially actionable results <40% endorsed disclosure of uncertain genomic findings Respondents noted significant variation in language physicians use to describe genomic testing |
| Miller 2014 | Canada | 14 | Medical oncologists | Semistructured interviews | Attitudes and expectations regarding primary results Attitudes toward secondary findings | Optimistic about long-term potential but cautious about immediate benefits and mindful of elevated patient expectations Consent and counseling expected to mitigate challenges from incidental findings |
| Gornick 2018 | U.S. | 43 | Medical oncologists who had referred 112 patients to a genomic sequencing program | Online survey sent after each patient enrolled | Intended use of sequencing information | Intended to share results with 84% of patients Planned to make treatment changes for 24 (22%) of patients based on results, but only 9 of 24 actually had changes |
| Study . | Country . | Sample size . | Physicians . | Type of survey . | Dimensions and measures . | Main findings . |
|---|---|---|---|---|---|---|
| Chow-White 2017 | Canada | 31 | Medical oncologists (actively involved in clinical genomics trial) | Web-based questionnaire | Knowledge (self-perceived) Attitudes, concerns, and expectations regarding primary results | Low to moderate level of genomic literacy 42% thought medical training programs do not offer enough genomic training Majority thought genomics will have a major impact on drug discovery and treatment selection in the next 5 years Major challenges considered to be cost, patient genomic literacy, and clinical utility of genomics |
| Gray 2016 | U.S. | 27 | Medical oncologists with extensive experience ordering tumor NGS (median 100 per year) | Self-administered questionnaire (in person or by telephone) Follow-up interview | Knowledge (self-perceived) Attitudes about return of results | 97% moderately to very confident in their ability to interpret somatic results in their disease area, to explain concepts to patients, and to make treatment recommendations based on somatic information 78% wanted to disclose results if they have clinical utility, 67% if no clinical utility Some expressed concern about management of patients’ expectations and how much of the information should be shared with patients |
| Gray 2014 | U.S. | 160 | Medical, radiation, and surgical oncologists | Web survey | Knowledge (self-perceived) Attitudes and expectations regarding primary results Attitude toward secondary findings | Considerable variation in genomic confidence with 22% reporting low confidence in genomic knowledge Higher genomic confidence was associated with wanting to test a majority of patients Variation in attitudes about value of testing Between 70% and 90% endorsed disclosure of actionable or potentially actionable results <40% endorsed disclosure of uncertain genomic findings Respondents noted significant variation in language physicians use to describe genomic testing |
| Miller 2014 | Canada | 14 | Medical oncologists | Semistructured interviews | Attitudes and expectations regarding primary results Attitudes toward secondary findings | Optimistic about long-term potential but cautious about immediate benefits and mindful of elevated patient expectations Consent and counseling expected to mitigate challenges from incidental findings |
| Gornick 2018 | U.S. | 43 | Medical oncologists who had referred 112 patients to a genomic sequencing program | Online survey sent after each patient enrolled | Intended use of sequencing information | Intended to share results with 84% of patients Planned to make treatment changes for 24 (22%) of patients based on results, but only 9 of 24 actually had changes |
Studies evaluating knowledge and attitudes of oncologists regarding tumor next-generation sequencing
| Study . | Country . | Sample size . | Physicians . | Type of survey . | Dimensions and measures . | Main findings . |
|---|---|---|---|---|---|---|
| Chow-White 2017 | Canada | 31 | Medical oncologists (actively involved in clinical genomics trial) | Web-based questionnaire | Knowledge (self-perceived) Attitudes, concerns, and expectations regarding primary results | Low to moderate level of genomic literacy 42% thought medical training programs do not offer enough genomic training Majority thought genomics will have a major impact on drug discovery and treatment selection in the next 5 years Major challenges considered to be cost, patient genomic literacy, and clinical utility of genomics |
| Gray 2016 | U.S. | 27 | Medical oncologists with extensive experience ordering tumor NGS (median 100 per year) | Self-administered questionnaire (in person or by telephone) Follow-up interview | Knowledge (self-perceived) Attitudes about return of results | 97% moderately to very confident in their ability to interpret somatic results in their disease area, to explain concepts to patients, and to make treatment recommendations based on somatic information 78% wanted to disclose results if they have clinical utility, 67% if no clinical utility Some expressed concern about management of patients’ expectations and how much of the information should be shared with patients |
| Gray 2014 | U.S. | 160 | Medical, radiation, and surgical oncologists | Web survey | Knowledge (self-perceived) Attitudes and expectations regarding primary results Attitude toward secondary findings | Considerable variation in genomic confidence with 22% reporting low confidence in genomic knowledge Higher genomic confidence was associated with wanting to test a majority of patients Variation in attitudes about value of testing Between 70% and 90% endorsed disclosure of actionable or potentially actionable results <40% endorsed disclosure of uncertain genomic findings Respondents noted significant variation in language physicians use to describe genomic testing |
| Miller 2014 | Canada | 14 | Medical oncologists | Semistructured interviews | Attitudes and expectations regarding primary results Attitudes toward secondary findings | Optimistic about long-term potential but cautious about immediate benefits and mindful of elevated patient expectations Consent and counseling expected to mitigate challenges from incidental findings |
| Gornick 2018 | U.S. | 43 | Medical oncologists who had referred 112 patients to a genomic sequencing program | Online survey sent after each patient enrolled | Intended use of sequencing information | Intended to share results with 84% of patients Planned to make treatment changes for 24 (22%) of patients based on results, but only 9 of 24 actually had changes |
| Study . | Country . | Sample size . | Physicians . | Type of survey . | Dimensions and measures . | Main findings . |
|---|---|---|---|---|---|---|
| Chow-White 2017 | Canada | 31 | Medical oncologists (actively involved in clinical genomics trial) | Web-based questionnaire | Knowledge (self-perceived) Attitudes, concerns, and expectations regarding primary results | Low to moderate level of genomic literacy 42% thought medical training programs do not offer enough genomic training Majority thought genomics will have a major impact on drug discovery and treatment selection in the next 5 years Major challenges considered to be cost, patient genomic literacy, and clinical utility of genomics |
| Gray 2016 | U.S. | 27 | Medical oncologists with extensive experience ordering tumor NGS (median 100 per year) | Self-administered questionnaire (in person or by telephone) Follow-up interview | Knowledge (self-perceived) Attitudes about return of results | 97% moderately to very confident in their ability to interpret somatic results in their disease area, to explain concepts to patients, and to make treatment recommendations based on somatic information 78% wanted to disclose results if they have clinical utility, 67% if no clinical utility Some expressed concern about management of patients’ expectations and how much of the information should be shared with patients |
| Gray 2014 | U.S. | 160 | Medical, radiation, and surgical oncologists | Web survey | Knowledge (self-perceived) Attitudes and expectations regarding primary results Attitude toward secondary findings | Considerable variation in genomic confidence with 22% reporting low confidence in genomic knowledge Higher genomic confidence was associated with wanting to test a majority of patients Variation in attitudes about value of testing Between 70% and 90% endorsed disclosure of actionable or potentially actionable results <40% endorsed disclosure of uncertain genomic findings Respondents noted significant variation in language physicians use to describe genomic testing |
| Miller 2014 | Canada | 14 | Medical oncologists | Semistructured interviews | Attitudes and expectations regarding primary results Attitudes toward secondary findings | Optimistic about long-term potential but cautious about immediate benefits and mindful of elevated patient expectations Consent and counseling expected to mitigate challenges from incidental findings |
| Gornick 2018 | U.S. | 43 | Medical oncologists who had referred 112 patients to a genomic sequencing program | Online survey sent after each patient enrolled | Intended use of sequencing information | Intended to share results with 84% of patients Planned to make treatment changes for 24 (22%) of patients based on results, but only 9 of 24 actually had changes |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
